Fig. 4From: Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case reportPreoperative and postoperative tumor marker results: carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA19-9). Abbreviations: SD, stable disease; PD, progressive disease; PR, partial responseBack to article page